Better Growth Stock: Abbott vs. AbbVie
Abbott Laboratories (NYSE: ABT) and (NYSE: ABBV) share a common past. About a decade ago, Abbott spun out its pharmaceuticals business into a separate company to create AbbVie. Since then, both companies have grown revenue and net income in the triple digits. At the same time, they've steadily increased dividends year after year, offering shareholders passive income growth too.
After last year's stock market gains, you may be looking toward the next bull market and aiming to prepare by scooping up growth stocks. Both Abbott and AbbVie could fit into your strategy. But, if you could only buy one, which should you choose? Let's find out which one of these healthcare companies makes the better growth stock to buy now.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Aktie
Mit 32 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung ist AbbVie Inc. einer der Lieblinge unserere Community.
Das von der Community festgelegte Kursziel von 209 € für AbbVie Inc. deutet auf ein leichtes Wachstumspotenzial im Vergleich zu 177.8 € hin.
